GeNeuro provided an update on GNbAC1, its multiple sclerosis drug candidate. GNbAC1, the first drug candidate directly targeting a potential cause of MS, is a monoclonal antibody designed to neutralise MSRV-Env, a pathogenic protein which has been associated with both the inflammatory and neurodegenerative components of the disease. Full enrollment of the CHANGE-MS Phase 2b study of GNbAC1 has been completed, several months ahead of schedule, and is indicative of strong interest from physicians in this pioneering new treatment for MS. Based on this accelerated timeline, GeNeuro now expects the availability of top-line results from this study early in the fourth quarter of 2017, versus the previous estimate of by year-end 2017. The double-blind, placebo-controlled study, CHANGE-MS (Clinical trial assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in Multiple Sclerosis), is evaluating the efficacy of GNbAC1 in reducing the number of new inflammatory lesions as well as measures of neurodegeneration on brain MRI in patients with remitting relapsing multiple sclerosis (RRMS). The CHANGE-MS Phase 2b study is fully funded through GeNeuro’s €362.5 million1partnership with Servier, which was signed in 2014. The recently announced ANGEL-MS (Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an open label Long-term Safety Study in patients with Multiple Sclerosis) study has now been launched, offering all patients having completed the Phase IIb CHANGE-MS study the opportunity to continue their treatment for an additional two years, providing additional efficacy and tolerance data. The first patient completing 12 months in CHANGE-MS, eligible to continuing treatment through ANGEL-MS, is expected to enrol in April 2017. Like CHANGE-MS, the ANGEL-MS study will be fully funded by Servier. GeNeuro continues to work on its submission package in preparation for clinical trials in the U.S. A Phase 2 study in secondary progressive MS patients, a patient population distinct from RRMS patients, is now anticipated to begin during the second half of 2017. This study will evaluate the effect of repeated doses of GNbAC1 on safety and biomarkers of microglial activation, remyelination and neuroprotection.